We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
ESTRO
Menu
  • Corporate Members
  • E-Library
  • Twitter
  • Linked In
  • Facebook
  • Instagram
  • Join
  • MyESTRO
Search Opener
  • About ESTRO
  • Membership
  • School
  • Workshops
  • Congresses
  • Science
  • Education
  • Advocacy
  • Corporate Members
  • E-Library
  1. Home
  2. About ESTRO
  3. Newsroom
  4. Newsletter
  5. Read it before your patients

Achieve recognition of all radiotherapy professions

Read it before your patients
  • 08/10/2024

    Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial

  • 04/10/2024

    Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer

  • 30/09/2024

    A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE)

  • 27/09/2024

    Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

  • 24/09/2024

    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment

  • 20/09/2024

    Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial

News Pages: 1 2 3 4 5 6 7 8 9 10
  • Newsletter 2019
  • Newsletter 2018
  • Newsletter 2017

Corner Editor: Philippe Lambin

Submit your article

Corner Editor: Evert van Limbergen

Submit your article
  • Contact
  • Privacy Statement
  • Sitemap
  • Careers
  • FAQ
  • Twitter
  • Linked In
  • Facebook
  • Instagram

© The European SocieTy for Radiotherapy and Oncology. All rights reserved. ESTRO Avenue Marnix 17, 1000 Brussels . +32 477 271 125.